non-fasting lipid profiles: implications for lipoprotein...
TRANSCRIPT
![Page 1: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/1.jpg)
Non-fasting lipid profiles: implications for lipoprotein testing and
reportingConsensus guideline of the European Atherosclerosis Society (EAS) and
European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
presenter: Michel Langlois MD,PhD
AZ St.-Jan Bruges & University of Ghent, BelgiumChair of EFLM Task & Finish Group – Laboratory Testing for Dyslipidemia
EFLM webinar
moderator: prof. Dr. Jerzy-Roch Noferleader of the scientific Clinical Chemistry division at the University of Münster.
![Page 2: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/2.jpg)
About Presenter• Professor at Ghent University, Department of Cardiovascular
Diseases• Vice-Director at the laboratory of AZ St-Jan hospital, Bruges• President of the Belgian Atherosclerosis Society• Past-president of the Royal Belgian Society of Laboratory Medicine• Chair of the EFLM-EAS Task and Finish Group on Laboratory
Testing for Dyslipidemia• Member of the EFLM WG-Guidelines• Corresponding member for the EFLM WG-Cardiac Markers and
WG-Congresses and Postgraduate Education
![Page 3: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/3.jpg)
Non-fasting Lipid Profiles: EAS-EFLM Consensus Statement
1. Why has fasting been the standard?
2. Which lipoproteins are atherogenic?
3. Influence of food intake on lipid tests?
4. Non-fasting lipid tests: fit for purpose?
5. Implications & guidelines for laboratories
![Page 4: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/4.jpg)
• Postprandial variation of Triglycerides (TG)
• Calculation of LDL-cholesterol (LDLC)Friedewald equation:LDLC = TC – HDLC – TG/2.2(mmol/l)
TG/5 (mg/dl)
Fasting Lipid Profiles: Why?
Invalid when TG >4.5 mmol/l (400 mg/dl)
![Page 5: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/5.jpg)
• Practical§ Patients§ Healthcare practitioners§ Laboratories
• MedicalDaily average lipid status is nonfasting
Fasting Lipid Profiles: disadvantages
![Page 6: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/6.jpg)
QUESTION 1:
Fasting LDL-C sufficiently estimates dyslipidemia-related risk in all patients?• YES• NO
![Page 7: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/7.jpg)
Non-fasting Lipid Profiles: EAS-EFLM Consensus Statement
1. Why has fasting been the standard?
2. Which lipoproteins are atherogenic?
3. Influence of food intake on lipid tests?
4. Non-fasting lipid tests: fit for purpose?
5. Implications & guidelines for laboratories
![Page 8: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/8.jpg)
Atherogenic lipoproteins
• Remnant particles
• LDL-particles
• Lipoprotein(a)
B
![Page 9: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/9.jpg)
![Page 10: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/10.jpg)
B. NordestgaardA. VarboThe Lancet 2014; 384:626-635
![Page 11: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/11.jpg)
A.Varbo et al. Copenhagen General Population Study, Copenhagen City Heart Study, & Copenhagen Ischemic Heart Disease Study. J Am Coll Cardiol 2013;61:427-36.
Remnant cholesterol is a direct, causal CVD risk factor
![Page 12: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/12.jpg)
LDL-particles
![Page 13: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/13.jpg)
Low LDL-C; underestimated risk
Misleading LDL-C
Atherogenic Dyslipidemia in Diabetes and the Metabolic Syndrome
![Page 14: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/14.jpg)
Lp(a)
LDL particle + apo(a)
2 to >40 KIV2repeats
![Page 15: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/15.jpg)
HDL
VLDL
IDL
Chylo-microns
Lp(a)
LDL
LDLCHDLC
ChylomicronRemnants
Den
sity
(g/m
l)
TC
Size
![Page 16: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/16.jpg)
HDL
VLDL
IDL
Chylo-microns
Lp(a)
LDL
LDLCHDLC ‘Remnant-C’
Non-HDLC
ChylomicronRemnants
ApoB ApoA-I
Den
sity
(g/m
l)
TC
Size
![Page 17: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/17.jpg)
Non-fasting Lipid Profiles: EAS-EFLM Consensus Statement
1. Why has fasting been the standard?
2. Which lipoproteins are atherogenic?
3. Influence of food intake on lipid tests?
4. Non-fasting lipid tests: fit for purpose?
5. Implications & guidelines for laboratories
![Page 18: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/18.jpg)
QUESTION 2:
Food intake significantly influences lipid tests ?
• YES
• NO
![Page 19: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/19.jpg)
![Page 20: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/20.jpg)
![Page 21: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/21.jpg)
A. Langsted et al. Circulation 2008;118:2047-2056.
![Page 22: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/22.jpg)
![Page 23: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/23.jpg)
Non-fasting Lipid Profiles: EAS-EFLM Consensus Statement
1. Why has fasting been the standard?
2. Which lipoproteins are atherogenic?
3. Influence of food intake on lipid tests?
4. Non-fasting lipid tests: fit for purpose?
5. Implications & guidelines for laboratories
![Page 24: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/24.jpg)
Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016
![Page 25: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/25.jpg)
Population-based studies N >300 000 non-fasting individuals
Statin trials N= 43 000 non-fasting individuals
Tromsø Heart Study Heart Protection Study
Norwegian National Health Service Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm
British Population Studies Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
European Prospective Investigation of Cancer–Norfolk
Northwick Park Heart StudyApolipoprotein-related Mortality RiskCopenhagen City Heart StudyWomen's Health StudyNurses' Health StudyPhysicians' Health Study
National Health and Nutrition Examination Survey III
Circulatory Risk in Communities StudyCopenhagen General Population Study
INTERHEART study
Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016
![Page 26: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/26.jpg)
![Page 27: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/27.jpg)
• Potential for risk misclassification in hypertriglyceridemic samples!
![Page 28: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/28.jpg)
Abbott Beckman Olympus Roche Siemens Ortho
1.3
1.2
1.1
1.0
0.9
0.8
0.7
0.6
Langlois M et al. The EAS-EFLM Collaborative Project. Atherosclerosis 2014; 233:83-90
1.08CDC Reference Laboratory,Rotterdam
EQA survey (n=197 labs) of hypertriglyceridemic serum (~7 mmol/l)
Risk cutpoint
![Page 29: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/29.jpg)
In red: SCORE>5 % and LDL-C ³ 2.50 mmol/L: start statin therapy immediately In green: SCORE>5 % and LDL-C <2.50 mmol/L: not applicable for statin therapy.
Clinical simulation: effect of direct LDL-C method variation on treatment
![Page 30: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/30.jpg)
= TC - HDLC
![Page 31: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/31.jpg)
A.Varbo et al. Copenhagen General Population Study. J Am Coll Cardiol 2013;61:427-36.
Non-fasting non-HDLC includes ‘remnant-cholesterol’
![Page 32: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/32.jpg)
Abbott Beckman Olympus Roche Siemens Ortho
5.3
5.1
4.9
4.7
4.5
4.3
Langlois M et al. The EAS-EFLM Collaborative Project. Atherosclerosis 2014; 233:83-90
EQA survey (n=197 labs) of hypertriglyceridemic serum
![Page 33: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/33.jpg)
In cases with TG 200-400 mg/dL(2.3-4.5 mmol/L)
De, Denka; Ky, Kyowa; Ro, Roche; Sr, Serotec; Sk, Sekisui, Sy, Sysmex; Um, UMA; Wa, Wako.
van Deventer HE et al. Clin Chem 2011;57:490-501
Misclassification of CVD risk(A) direct LDLC(B) calculated LDLC(C) non–HDLCcompared to Reference Method
![Page 34: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/34.jpg)
TG
CC CTG
C
VLDL VLDL remnant
Small dense LDL
Large LDL
apoB apoB apoB apoB
ApoB : marker of atherogenic particle number
TG: triglycerides C: cholesterol
B B B B
![Page 35: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/35.jpg)
<1%
<10%
~90%
ApoB48
ApoB100
Non-fasting apoB
![Page 36: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/36.jpg)
Apo B 0.6 g/l Apo B 1.2 g/l
LDL cholesterol 100 mg/dl
Triglycerides 120 mg/dl
LDL cholesterol 100 mg/dl
Triglycerides 300 mg/dl
B B B
B B B
B B B B
B
B B B B
B
ApoB vs. LDLC
BB
![Page 37: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/37.jpg)
I. van den Broek et al. Clin Chem 2016;62:188-97.
ApoB assays: traceable to WHO/IFCC reference material
NTG: normotriglyceridemia, HTG: hypertriglyceridemia, ITA: immunoturbidimetric assay
![Page 38: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/38.jpg)
• Non-HDLC§ Calculated as TC – HDLC at no additional cost§ Includes ‘remnant-C’§ Not influenced by TG variability§ HDLC measurement errors!
• ApoB§ Simple, automated assay§ Single, well-defined measurand§ International standard SP3-08 (WHO / IFCC)§ LDL-particle number count
Non-fasting lipoprotein markers beyond LDLC
![Page 39: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/39.jpg)
Comparison of 26 lipid fractions as predictors of first-ever cardiovascular events in apparently healthy women. Data are shown for the top versus bottom quintile of each lipid fraction.
The Lancet 2014;384:607 - 617
Paul M Ridker LDL cholesterol: controversies and future therapeutic directions
![Page 40: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/40.jpg)
Relative Risk Ratios (RRR) for LDLC, non-HDLC, and apoBfrom 12 independent epidemiological studies
Sniderman A et al. Circ Cardiovasc Qual Outcomes 2011;4:337-345
LDL-C 1.25 (1.18-1.33) non-HDL-C 1.34 (1.24-1.44) ApoB 1.43 (1.35-1.51)
![Page 41: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/41.jpg)
Coronary heart disease (CHD) risk among 13 595 women with LDLC < Median (120 mg/dl)
S.Mora et al. Women’s Health Study. Circulation 2014;129:553-61
![Page 42: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/42.jpg)
Copyright © 2014 American Medical Association. All rights reserved.
From: Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins: Meta-analysis of 8 Trials (N=38 153)
Boekholdt SM et al. JAMA. 2012;307:1302-1309.
Hazard ratios (HRs) and 95% CIs for risk of major cardiovascular events for 4 categories of statin-treated patients, based on whether or not they reached the LDL-C target of 100 mg/dL and the non–HDL-C target of 130 mg/dL. HRs were adjusted for sex, age, smoking, diabetes, systolic blood pressure, and trial.
![Page 43: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/43.jpg)
Jepsen AK et al. Clin Chem 2016;62:593-604
Remnant cholesterol explains part of residual risk of mortalityin 5414 patients with ischemic heart disease
![Page 44: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/44.jpg)
“The good,
the bad,
and the ugly”
Non-fasting lipid profile
![Page 45: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/45.jpg)
Non-fasting Lipid Profiles: EAS-EFLM Consensus Statement
1. Why has fasting been the standard?
2. Which lipoproteins are atherogenic?
3. Influence of food intake on lipid tests?
4. Non-fasting lipid tests: fit for purpose?
5. Implications & guidelines for laboratories
![Page 46: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/46.jpg)
QUESTION 3:
Fasting lipid tests are obsolete and should not be used anymore?
• YES
• NO
![Page 47: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/47.jpg)
Key recommendations
Fasting is not routinely required for a lipid profile
At nonfasting TG >4.5mmol/L (>400mg/dL), fasting sampling should be considered
Laboratory reports should flag abnormal concentrations based on desirable cutpoints
Life-threatening or extremely high concentrations should trigger lipid clinic referral
Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016
EAS-EFLM Consensus GuidelinePublished in Eur Heart J 2016 and Clin Chem 2016
![Page 48: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/48.jpg)
Non-fasting In most patients, including:
· Initial lipid profile testing in any patient
· For CVD risk assessment
· Follow-up of cholesterol-lowering therapy
· In children
· If preferred by the patient
· In diabetic patients (due to hypoglycemic risk)
· In elderly
Fasting Rarely, but fasting can be used if:
· Nonfasting TG >5 mmol/L (>400 mg/dL)
· Diagnosis and follow-up of high TG known in lipid clinic
· Other tests that require fasting, e.g., glycemia
When to use non-fasting and fasting lipid tests?
Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016
![Page 49: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/49.jpg)
Risk cutpoints Units
mmol/L mg/dL
Triglycerides Fasting
Nonfasting
≥1.7
≥2
≥150
≥175
Total cholesterol ≥5 ≥190
LDL cholesterol ≥3 ≥115
Non-HDL cholesterol Fasting
Nonfasting
≥3.8
≥3.9
≥145
≥150
Lipoprotein(a) ≥50
HDL cholesterol ≤1 ≤40
g/L mg/dL
Apolipoprotein B ≥1 ≥100
Apolipoprotein A1 ≤1.2 ≤120
=LDL-C + TG/5
![Page 50: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/50.jpg)
Risk
SCORE (%)
LDL-C
mg/dl (mmol/l)
Non-HDL-C *
mg/dl (mmol/l)
ApoB *
mg/dl (g/l)
Very high (≥10) < 70 (1.8) < 100 (2.6) < 80 (0.8)
High (5 - <10) < 100 (2.5) < 130 (3.3) < 100 (1.0)
Moderate (1 - <5) < 115 (3.0) < 145 (3.8)
*Secondary targets in patients with combined dyslipidemia, metabolicsyndrome, type 2 diabetes, or chronic kidney disease.
Primary and secondary targets of therapy
Catapano A et al. ESC/EAS Guidelines for Dyslipidemia Management. Atherosclerosis 2011;217:3-46
![Page 51: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/51.jpg)
Definition of hypertriglyceridemia by EAS Consensus
• Mild-to-Moderate§ 175 - 880 mg/dl (2 - 10 mmol/l)§ non-HDLC or apoB secondary target
• Severe§ >880 mg/dl (> 10 mmol/l)§ Prevention of pancreatitis
Hegele RA et al. Lancet Diabetes Endocrinol 2014;2:655-66.
![Page 52: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/52.jpg)
![Page 53: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/53.jpg)
Life-threatening
concentrations
Refer patient to lipid specialist to rule out
TG >10 mmol/L
>880 mg/dL
Chylomicronemia syndrome:
high risk of acute pancreatitis
LDL-C >5 mmol/L
>190 mg/dL
Heterozygous Familial Hypercholesterolemia (FH):
high CVD risk
LDL-C >13 mmol/L
>500 mg/dL
Homozygous Familial Hypercholesterolemia (FH):
very high CVD risk
Lp(a) >150 mg/dL Very high risk of myocardial infarction and
aortic valve stenosis
“Alarm” concentration flagging and reporting
Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016
® Family cascade screening
![Page 54: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/54.jpg)
Dutch Lipid Clinical Network Criteria Score
Family historyFirst-degree relative with premature coronary and/or vascular disease (men <55 yrs, women <60 yrs) OR with LDL-C >95th percentile 1
First-degree relative with tendinous xanthomata and/or arcus cornealisOR Children <18 yrs with LDL-C >95th percentile 2
Clinical historyPremature coronary artery disease (men <55 yrs, women <60 yrs) 2Premature cerebral or peripheral vascular disease (men <55 yrs, women <60 yrs) 1Physical examinationTendinous xanthomata 6Arcus cornealis before 45 yrs 4Causative mutation in LDL-R, APOB or PCSK9 genes 8LDL-cholesterol ≥8.5 mmol/L (330 mg/dL) 8
6.5–8.4 mmol/L (250–329 mg/dL) 55.0–6.4 mmol/L (190–249 mg/dL) 34.0–4.9 mmol/L (155–189 mg/dL) 1
Diagnosis Total score
Definite FH >8Probable FH 6-8Possible FH 3-5Unlikely FH <3
![Page 55: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/55.jpg)
National Societies for cardiology, endocrinology, atherosclerosis, pediatrics, clinical chemistry, general practice etc.
Key university hospitals and reference centers
National Implementation Strategies
Journalists and key medias disseminate the story that fasting is no longer routinely required for lipid testing
Clinical chemistry laboratories no longer require fasting for lipid testing and use desirable concentration cutpoints for lipid test reporting and flagging
![Page 56: Non-fasting lipid profiles: implications for lipoprotein ...eflm.eu/files/efcc/EFLM_webinar_non-fasting_lipids_42016_handouts… · § 175 - 880 mg/dl (2 - 10 mmol/l) § non-HDLC](https://reader034.vdocuments.us/reader034/viewer/2022042915/5f538faa37cbdf6d2b262b1f/html5/thumbnails/56.jpg)
From EFLM: Michel Langlois (Belgium; EFLM co-chair)Hannsjörg Baum (Germany), Christa Cobbaert (The Netherlands), Kari Pulkki (Finland), Grazyna Sypniewska (Poland)From EAS: Børge Nordestgaard (Denmark; EAS co-chair)Jan Borén (Sweden), Olivier Descamps (Belgium), Arnold von Eckardstein (Switzerland), Olov Wiklund (Sweden)Invited expertsEric Bruckert (France), John Chapman (France), Pia Kamstrup (Denmark), Genovefa Kolovou (Greece), Florian Kronenberg (Austria), Anne Langsted (Denmark), Samia Mora (USA), Alan Remaley (USA), Nader Rifai (USA), Emilio Ros (Spain), Gerald Watts ( Australia)
EAS-EFLM Consensus Panelestablished in 2014